Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.34 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31457111 | 1.00 | ERN1 (0.52) | ERN1CYP2A6PTGDR2ALDH1A3PTPN1 | |
| SCHEMBL3208498 | 0.84 | ERN1 (0.47) | ERN1CYP2A6PTGDR2ALDH1A3PTPN1 | |
| SCHEMBL2042638 | 0.80 | NCEH1 (0.41) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL6102737 | 0.80 | ALDH1A3 (0.46) | ERN1CYP2A6PTGDR2ALDH1A3PTPN1 | |
| SCHEMBL7526844 | 0.80 | ERN1 (0.34) | ERN1ALDH1A1APPPOLBMAPK1 | |
| SCHEMBL6103005 | 0.79 | ERN1 (0.43) | ERN1CYP2A6PTGDR2ALDH1A3PTPN1 | |
| SCHEMBL10364078 | 0.78 | ALDH1A1 (0.49) | ERN1CYP2A6ALDH1A3ALDH1A1MAPK1 | |
| SCHEMBL5685311 | 0.78 | ALDH1A3 (0.49) | CYP2A6ALDH1A3ALDH1A1APPALDH3A1 | |
| SCHEMBL30893368 | 0.78 | ALDH1A3 (0.49) | CYP2A6ALDH1A3ALDH1A1APPALDH3A1 | |
| SCHEMBL6104478 | 0.77 | ERN1 (0.41) | ERN1CYP2A6PTGDR2ALDH1A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | disclosed |
| CN-101558038-B | Curcumin derivative | TOKYO INST TECH | 2013-05-01 | — | — | CN | disclosed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2123637-A1 | NOVEL CURCUMIN DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-11-25 | — | — | EP | disclosed |
| CN-101558038-A | Novel curcumin derivative | TOKYO INST TECH (JP) | 2009-10-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | ERN1 2254/4885CYP2A6 3242/4885PTGDR2 3455/4885 |
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | ERN1 3748/4885CYP2A6 417/4885PTGDR2 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.